Please login to the form below

TNBC

This page shows the latest TNBC news and features for those working in and with pharma, biotech and healthcare.

Triplet approvals for myeloma boost Celgene in Q2

Abraxane is enjoying a sales surge thanks to its use in combination with cancer immunotherapies in indications like non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC), according

Latest news

Keytruda scores in neoadjuvant triple negative breast cancer combo

Tecentriq still in pole position. Merck &Co. has announced positive early results from its phase 3 trial of Keytruda as a neoadjuvant treatment for patients with triple-negative breast cancer (TNBC). ... in patients with unresectable locally advanced or
BioNTech raises €290m for mRNA cancer vaccine platform

TNBC) in phase 1.
Keytruda monotherapy fails in triple negative breast cancer

That approval was a first for checkpoint inhibitors in TNBC, but differed in that it was a combination of Tecentriq and chemotherapy (Celgene’s Abraxane, nab-paclitaxel). ... placebo plus chemotherapy for previously untreated locally recurrent
Tecentriq combo shows promise in triple negative breast cancer

to assess treatment-related biomarker changes in TNBC patients who have progressed after at least one line of chemo. ... While Roche has sprung into the lead in the therapy area, Merck &Co is expecting results of two TNBC studies to emerge soon.
Tecentriq gains first IO approval in triple negative breast cancer

This is based on Keytruda’s tally of 14 FDA approvals, while the TNBC approval is Tecentriq’s fourth. ... compared with Abraxane alone in PD-L1-positive patients with unresectable locally advanced or metastatic TNBC who had not received prior

More from news
Approximately 3 fully matching, plus 17 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer
Deal Watch February 2017

triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. . ... IMMU-132 has FDA Breakthrough Therapy designation for the treatment of patients with TNBC who have failed prior

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)

cell carcinoma, Merkel cell carcinoma, and triple-negative breast cancer (TNBC) via chest-wall lesions.8. ... trocar. Further, TAVO has already proven to show robust efficacy in difficult-to-treat patient populations, including metastatic melanoma

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

FREELANCE Account Director – Healthcare Advertising – London – 3...: Competitive Daily Rates

Account Director – UK Office: Excellent salary and benefits

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Account Director - Healthcare Advertising - London - 2 DAYS HOME...: £50000 - £70000

Account Director, Healthcare Communications: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Empowered patients: shaking the foundations of healthcare: Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service: The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence: Data is the most valued commodity of the modern world. For P&P it's all about the application....